Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
We spoke with Head of Human Resources, North America, Clint Wallace, about why the company was named a Seramount 100 Best Company. Sanofi's Clint Wallace discusses why the company was named a ...
On March 9, 2010, Sanofi-Aventis announced [6] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint ...
Sanofi has managed the daunting task faced by managers worldwide: hauling its employees back to the office with minimal fuss. That’s an impressive feat for a company that said last year it was ...
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...
Sanofi Selects BioClinica's OnPoint as Enterprise CTMS - Global Healthcare Leader Becomes the Latest Pharmaceutical Company to Choose BioClinica's Industry-Leading Clinical Trial Management System ...
The company is a subsidiary of the French multinational pharmaceutical company Sanofi. The company’s brands are sold nationally through mass merchandiser, drug and food retailers. In 2005, 70% of the firm's sales were made through its top ten customers, which include Wal-Mart , Walgreens , and Kroger.
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...